Johns Hopkins ABX Guide
Dolutegravir
INDICATIONS
FDA
FDA
Tivicay: Treatment of HIV-1 infection in combination with other ARV agents in adults and children weighing ≥30 kg
Triumeq: Treatment of HIV-1 infection in adults and children weighing ≥40 kg
Juluca: Treatment of HIV-1 infection as a complete regimen for adult patients already virologically suppressed on stable ART for 6 months and no known resistance to dolutegravir or rilpivirine
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Non-occupational post-exposure prophylaxis (nPEP) in combination with other ARV agents
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 13, 2018
Citation
Smith, Janessa, and Paul A Pham. "Dolutegravir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540660/all/Dolutegravir.
Smith J, Pham PA. Dolutegravir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540660/all/Dolutegravir. Accessed December 7, 2023.
Smith, J., & Pham, P. A. (2018). Dolutegravir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540660/all/Dolutegravir
Smith J, Pham PA. Dolutegravir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2023 December 07]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540660/all/Dolutegravir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Dolutegravir
ID - 540660
A1 - Smith,Janessa,Pharm.D. BCPS
AU - Pham,Paul,Pharm.D., BCPS
Y1 - 2018/09/13/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540660/all/Dolutegravir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
